Drug Trial Radar · NCT00153062
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
Last checked: Nov 19, 2026Latest source record: May 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20,332
Actual
Start
Aug 2003
Primary completion
Apr 2008
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline; Bayer
- First posted
- Sep 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to determine if extended-release dipyridamole + aspirin \[Aggrenox, Asasa ntin\] is superior to clopidogrel \[Plavix\], and if telmisartan \[Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan\] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.
Conditions
- Stroke
Interventions
AggrenoxDrug
25mg aspirin, 200 mg dipyridamole
AggrenoxDrug
25mg aspirin, 200 mg dipyridamole
Clopidogrel placeboDrug
placebo
Clopidogrel placeboDrug
placebo
MicardisDrug
80 mg micardis
MicardisDrug
80 mg micardis
Aggrenox placeboDrug
placebo
Aggrenox placeboDrug
placebo
ClopidogrelDrug
75 mg clopidogrel
ClopidogrelDrug
75 mg clopidogrel
Micardis placeboDrug
placebo
Micardis placeboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)Time frame: time since randomization; follow-up period is 1.5 to 4.4 years
- Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)Time frame: time since randomization; follow-up period is 1.5 to 4.4 years
Locations
667 sites in 36 countries. Site status is shown where the registry gives one.
9.159.1101 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
9.159.1173 Boehringer Ingelheim Investigational Site
Huntsville, Alabama
9.159.1058 Boehringer Ingelheim Investigational Site
Mobile, Alabama
9.159.1087 Boehringer Ingelheim Investigational Site
Montgomery, Alabama
9.159.1081 Boehringer Ingelheim Investigational Site
Northport, Alabama
9.159.1022 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
9.159.1133 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
9.159.1149 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
9.159.1137 Boehringer Ingelheim Investigational Site
Tucson, Arizona
9.159.1184 Boehringer Ingelheim Investigational Site
Fayetteville, Arkansas
9.159.1005 Boehringer Ingelheim Investigational Site
Fort Smith, Arkansas
9.159.1136 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas
9.159.1062 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
9.159.1040 Boehringer Ingelheim Investigational Site
Berkeley, California
9.159.1180 Boehringer Ingelheim Investigational Site
Carmichael, California
9.159.1114 Boehringer Ingelheim Investigational Site
Irvine, California
9.159.1202 Boehringer Ingelheim Investigational Site
Laguna Hills, California
9.159.1036 Boehringer Ingelheim Investigational Site
Los Angeles, California
9.159.1052 Boehringer Ingelheim Investigational Site
Los Angeles, California
9.159.1100 Boehringer Ingelheim Investigational Site
Los Angeles, California
9.159.1111 Boehringer Ingelheim Investigational Site
Los Angeles, California
9.159.1165 Boehringer Ingelheim Investigational Site
Los Angeles, California
9.159.1134 Boehringer Ingelheim Investigational Site
Oceanside, California
9.159.1002 Boehringer Ingelheim Investigational Site
Palo Alto, California
9.159.1108 Boehringer Ingelheim Investigational Site
Redding, California
9.159.1013 Boehringer Ingelheim Investigational Site
Sacramento, California
9.159.1198 Boehringer Ingelheim Investigational Site
Sacramento, California
9.159.1029 Boehringer Ingelheim Investigational Site
San Diego, California
9.159.1185 Boehringer Ingelheim Investigational Site
San Francisco, California
9.159.1218 Boehringer Ingelheim Investigational Site
San Jose, California
9.159.1179 Boehringer Ingelheim Investigational Site
Santa Rosa, California
9.159.1162 Boehringer Ingelheim Investigational Site
Sylmar, California
9.159.1183 Boehringer Ingelheim Investigational Site
Torrance, California
9.159.1205 Boehringer Ingelheim Investigational Site
Walnut Creek, California
9.159.1118 Boehringer Ingelheim Investigational Site
Denver, Colorado
9.159.1045 Boehringer Ingelheim Investigational Site
Englewood, Colorado
9.159.1038 Boehringer Ingelheim Investigational Site
Danbury, Connecticut
9.159.1196 Boehringer Ingelheim Investigational Site
Fairfield, Connecticut
9.159.1018 Boehringer Ingelheim Investigational Site
Hartford, Connecticut
9.159.1080 Boehringer Ingelheim Investigational Site
Newark, Delaware
Showing 40 of 667 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.